NXL_OUT_1 [2025-03-19 16:57:46 -0400] 2370 Bytes | 614 tokens | Cum: 614 tkns (7.67% of 8k)
==========================================================================

Listen up, partner—it's 04:57:44 PM on Wednesday March 19, 2025 ET (UTC-0400), and I’m revved up about Nexalin Technology (NXL), climbing from 2.2 to 2.54. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Nexalin Technology:

C1 - Mar-14-25 09:00AM - Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
C2 - Mar-03-25 08:30AM - Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS ) Technology for Opioid and Other Substance Use Disorders
C3 - Feb-28-25 08:30AM - Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval
C4 - Feb-26-25 08:30AM - Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
C5 - Feb-18-25 08:30AM - Nexalin Technology Announces UCSD IRB Approval for use of HALO Clarity in Clinical Trials for mTBI and PTSD Treatment
C6 - Feb-10-25 09:00AM - Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
C7 - Feb-03-25 08:30AM - Nexalin's Breakthrough DIFS Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
C8 - Jan-23-25 11:00AM - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about Nexalin Technology (NXL)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of Nexalin Technology.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

NXL_OUT_3 [2025-03-19 16:57:57 -0400] 977 Bytes | 301 tokens | Cum: 917 tkns (11.46% of 8k)
==========================================================================

Showing C2 (chunk 1 of 8): C2:
**Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS ) Technology for Opioid and Other Substance Use Disorders**
Date: Mar-03-25 08:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/03/3035618/0/en/Nexalin-Technology-Receives-Notice-of-Allowance-from-the-USPTO-for-Patent-Covering-Deep-Intracranial-Frequency-Stimulation-DIFS-Technology-for-Opioid-and-Other-Substance-Use-Disord.html

March 03, 2025 08:30 ET| Source:Nexalin Technology, Inc.Nexalin Technology, Inc.

HOUSTON, TX, March 03, 2025 (GLOBE NEWSWIRE) --Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW)(the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO)

-- More? (MOR) or Next section? (NEX)

NXL_OUT_5 [2025-03-19 16:57:59 -0400] 1019 Bytes | 294 tokens | Cum: 1297 tkns (16.21% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-14T13:02:00Z - RedChip Companies, Inc.: Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedC...
A2 - 2025-03-14T13:04:20Z - Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Mon...
A3 - 2025-03-14T11:30:38Z - Nexalin Technology, Inc. (NASDAQ:NXL) VP Carolyn Hamby Shelton Buys 6,000 Shares...
A4 - 2025-03-03T14:00:31Z - Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial...
A5 - 2025-03-03T13:31:59Z - Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

NXL_OUT_7 [2025-03-19 16:58:01 -0400] 967 Bytes | 277 tokens | Cum: 1576 tkns (19.70% of 8k)
==========================================================================

Showing A1 (chunk 1 of 8): A1:
**RedChip Companies, Inc.: Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV**Date: 2025-03-14Source: {'uri': 'finanznachrichten.de', 'dataType': 'news', 'title': 'FinanzNachrichten.de'}URL: https://www.finanznachrichten.de/nachrichten-2025-03/64827332-redchip-companies-inc-nexalin-technology-and-calidi-biotherapeutics-interviews-to-air-on-the-redchip-small-stocks-big-money-show-on-bloomberg-tv-200.htmORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews i

-- More? (MOR) or Next section? (NEX)

NXL_OUT_9 [2025-03-19 16:58:02 -0400] 1054 Bytes | 301 tokens | Cum: 1879 tkns (23.49% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-10T14:00:00Z - Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
B2 - 2025-01-23T16:00:00Z - Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
B3 - 2024-12-23T15:00:00Z - Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
B4 - 2024-11-26T15:00:00Z - New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
B5 - 2024-11-01T14:34:00Z - Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
B6 - 2024-10-22T18:15:00Z - Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

NXL_OUT_11 [2025-03-19 16:58:08 -0400] 694 Bytes | 174 tokens | Cum: 2055 tkns (25.69% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/10/3023474/0/en/Nexalin-Appointed-as-Industry-Co-Chair-of-National-TBI-Registry-Coalition.htmlNexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, has been appointed as the Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This appointment reflects Nexalin's commitment to advancing TBI advocacy and research, particularly in collaboration with policymakers and stakeholders.

-- More? (MOR) or Next section? (NEX)

NXL_OUT_13 [2025-03-19 16:58:10 -0400] 531 Bytes | 131 tokens | Cum: 2289 tkns (28.61% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-14 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

Special Note Regarding Forward-Looking Stmnts

You should read the following discussion and analysis of financial condition and operating results together with our financial state...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

NXL_OUT_15 [2025-03-19 16:58:12 -0400] 967 Bytes | 201 tokens | Cum: 2492 tkns (31.15% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Special Note Regarding Forward-Looking Statements

You should read the following discussion and analysis of financial condition and operating results together with our financial statements and the related notes and other financial information included elsewhere in this Report. References in this Managements Discussion and Analysis of Financial Condition and Results of Operations to us, we, our, and similar terms refer to Nexalin Technology, Inc. This discussion contains forward-looking statements as that term is defined within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are subject to the safe harbor created by those sections. The events described in forward-looking statem

-- More? (MOR) or Next section? (NEX)

NXL_OUT_17 [2025-03-19 16:58:14 -0400] 967 Bytes | 185 tokens | Cum: 2679 tkns (33.49% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ents contained in this discussion may not occur. Generally, these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits from acquisitions that may be made by us, or projections involving anticipated revenues, earnings or other aspects of our operating results. The words may, will, expect, believe, anticipate, project, plan, intend, estimate, and continue, and their opposites and similar expressions, are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, which may influence the accuracy of the statements and the projections upon which the statements are based. Reference is made to

-- More? (MOR) or Next section? (NEX)

NXL_OUT_19 [2025-03-19 16:58:29 -0400] 4931 Bytes | 1327 tokens | Cum: 4013 tkns (50.16% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+---------------------+-----------------------+------------------------+--------------------------+------------------------+
| Prev Close: 2.20 | RSI (14): 47.72 | Perf Quarter: -38.13% | Insider Trans: 0.52% | Sales Q/Q: 32.35% | ROE: -221.05% |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+------------------------+
| Target Price: 3.00 | ATR (14): 0.30 | Index: - | Option/Short: No / Yes | Sales past 5Y: 150.87% | ROI: -206.94% |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+------------------------+
| Price: 2.45 | SMA20: 0.22% | Market Cap: 32.60M | Short Float: 3.28% | Income: -7.61M | Sales Surprise: 20.00% |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+------------------------+
| Change: 11.36% | SMA50: -12.69% | Shs Outstand: 13.30M | Short Ratio: 1.05 | Employees: 6 | EPS Surprise: - |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+------------------------+
| Volume: 104,009 | SMA200: 17.92% | Shs Float: 10.77M | Short Interest: 0.35M | Debt/Eq: 0.00 | P/E: - |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+------------------------+
| Avg Volume: 336.23K | Perf Week: 8.89% | Inst Own: 2.79% | Beta: 4.51 | Sales Y/Y TTM: 52.35% | Earnings: Feb 26 |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+------------------------+
| Rel Volume: 0.31 | Perf Month: -29.19% | Insider Own: 19.07% | Sales: 0.17M | Profit Margin: -4508.73% | |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+------------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: Nexalin Technology, Inc. (NXL) by Shelton Carolyn Hamby (Sr. VP - Quality, Regulatory) on 2025-03-12
- Common Stock: 6000 shares at $2.2 (I)

Inside Trans: Nexalin Technology, Inc. (NXL) by Owens David (Chief Medical Officer) on 2025-02-26
- Stock Option (right to buy): 139821 shares at $0 (D)
- Stock Option (right to buy): 654363 shares at $0 (D)
- Stock Option (right to buy): 125000 shares at $0 (D)

Inside Trans: Nexalin Technology, Inc. (NXL) by White Mark (President and CEO) on 2025-02-26
- Stock Option (right to buy): 447427 shares at $0 (D)
- Stock Option (right to buy): 939597 shares at $0 (D)

Inside Trans: Nexalin Technology, Inc. (NXL) by Shelton Carolyn Hamby (Senior VP) on 2024-12-31
- Common stock: 24000 shares at $0.85 (D) Footnote: Represents shares purchased after appointment as Senior Vice President, Quality, Regulatory and Clinical Affairs.
- Stock Option (right to buy): 90620 shares at $0 (D)

Inside Trans: Nexalin Technology, Inc. (NXL) by Owens David (Chief Medical Officer) on 2025-02-04
- Common stock: 1000 shares at $3.1 (D)

Inside Trans: Nexalin Technology, Inc. (NXL) by Owens David (Chief Medical Officer) on 2025-02-04
- Common stock: 1000 shares at $2.98 (D)

Inside Trans: Nexalin Technology, Inc. (NXL) by Owens David (Chief Medical Officer) on 2025-01-28
- Common stock: 1500 shares at $2.7 (D)

Inside Trans: Nexalin Technology, Inc. (NXL) by Kazden Alan (Unknown Title) on 2024-12-31
- Stock Option (right to buy): 262500 shares at $0 (D)

Inside Trans: Nexalin Technology, Inc. (NXL) by Owens David (Chief Medical Officer) on 2024-12-31
- Common stock: 1000 shares at $2.75 (D)
- Stock Option (right to buy): 262500 shares at $0 (D)

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

NXL_OUT_21 [2025-03-19 16:58:35 -0400] 561 Bytes | 131 tokens | Cum: 4500 tkns (56.25% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

NXL_IN_23 [2025-03-19 16:58:36 -0400] 126 Bytes | 29 tokens | Cum: 4629 tkns (57.86% of 8k)
==========================================================================

====================================
[2025-03-19 13:58:36] # Analysis Completed
Elapsed Time: 52.32 seconds